Chin W, Rocchi A; International Society of Technology Assessment in Health Care. Meeting.
Annu Meet Int Soc Technol Assess Health Care Int Soc Technol Assess Health Care Meet. 1998; 14: 34.
Axia Research, Toronto, Canada.
OBJECTIVE: An economic evaluation of carvedilol was conducted to document the costs and consequences of using carvedilol as an adjunctive therapy in patients with congestive heart failure (CHF). METHODS: A retrospective cost-utility analysis (CUA) was conducted based on data from four phase III clinical trials. Survival estimates were calculated for CHF patients treated with standard care (diuretic, digoxin and angiotensin-converting enzyme inhibitor) or standard care plus carvedilol. The types and quantities of health care resources utilized by patients with CHF were estimated and costed in 1996 Canadian dollars. Utility values for CHF were obtained from published literature. The economic evaluation was conducted from the perspective of a provincial Ministry of Health with a time horizon of 10 years. RESULTS: Survival estimates for CHF patients treated with standard care plus carvedilol were significantly higher than CHF patients treated with standard care alone. The cost-utility ratio for carvedilol was $7300/QALY. The economic evaluation was insensitive to changes in the amount and cost of resources. The main factor influencing the CUA was patient survival. The cost-utility ratio ranged up to $14900/QALY for the most pessimistic scenerio. CONCLUSIONS: Carvedilol provided a significant survival benefit over standard care in patients with CHF. This survival benefit generated a cost-utility ratio for carvedilol which was considered to be favorable for the adoption and appropriate utilization of new technologies. Sensitivity analyses demonstrated that survival, not the cost of health care resources, was the important element in the CUA of carvedilol.
Publication Types:
Keywords:
- Angiotensin-Converting Enzyme Inhibitors
- Carbazoles
- Cost-Benefit Analysis
- Costs and Cost Analysis
- Digoxin
- Diuretics
- Health Care Costs
- Health Resources
- Heart Failure
- Humans
- Propanolamines
- Quality-Adjusted Life Years
- carvedilol
- economics
- hsrmtgs
Other ID:
UI: 102234503
From Meeting Abstracts